Elbert Glover

Last updated

Elbert D. Glover (born 1945) is an American researcher and author in the field of tobacco addiction and smoking cessation. After several academic positions, he retired as professor emeritus at the University of Maryland at College Park School of Public Health where he served as Chairperson of the Department of Behavioral and Community Health from 2005 to his retirement in 2015. [1] [2] Moreover, he was entrepreneur, editor, publisher, co-founder and principal owner of Health Behavior and Policy Review, [1] [2] and co-founder, owner, editor, and publisher of American Journal of Health Behavior [1] [2] [3] and Tobacco Regulatory Science. [1] [2] [3] [4] Glover was the founder [1] [2] [5] of the American Academy of Health Behavior and served as its first president from 1997 to 2001. [1] [2] [6]

Contents

Biography

Glover was born at the Kingsville Naval Base in Kingsville, Texas, in 1945, where his father was stationed in the U.S. Navy. He is the oldest of eight children. Upon graduation from Roy Miller High School in Corpus Christi, Texas, in 1963, he attended Texas Tech University on a football scholarship and graduated in 1969. [1] [2] [7] In 1972, he received a master's degree from Texas A&I University since renamed Texas A&M Kingsville [1] [2] and in 1977 received a PhD from Texas Woman's University, all in health education. [1] [2] [5] [7]

His initial academic professorial position was as visiting assistant professor at Texas A&M University (1975–1976). [1] [2] Subsequently, he served as assistant professor at the University of Kansas (1976–1978) and Texas Christian University (1978–1982). Moreover, he served as associate professor and chair at Oklahoma State University (1982–1983) and associate professor at East Carolina University (1985–1988). While at East Carolina University he was promoted to professor. Thereafter, he served as professor at Pennsylvania State University (1988–1990) followed by a position as professor in behavioral medicine and psychiatry at West Virginia University School of Medicine (1990–2005). While at West Virginia University School of Medicine, he was also appointed as a professor in the Department of Family Medicine and Associate, Center for Addictions, Chestnut Hospital (1990–2005). He was founding director of the Tobacco Research Center, Mary Babb Randolph Cancer Center (1990–1999), founding director, Clinical Trials Research, Behavioral Medicine and Psychiatry (1999–2001) and founding director of the Addiction and Psychiatric Medicine Research Center (2001–2005) at West Virginia University School of Medicine. After his West Virginia University tenure, he accepted a professor and chairperson position at the University of Maryland at College Park School of Public Health (2005–2015). At the University of Maryland, he was the founding director of the Center for Health Behavior Research until his 2015 retirement where he was named professor emeritus in the Department of Behavioral and Community Health, School of Public Health. [1] [2] [7]

Research

Glover's research initially focused on smokeless tobacco; [1] [2] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] however, his primary research interest progressed to the development and testing of pharmacological cessation aids for smokers interested in stopping the addiction of tobacco. He conducted clinical trials with the use of all delivery forms of nicotine available on the US and European markets, to include nicotine gum, [18] [19] transdermal patches, [20] [21] oral nicotine inhalers, [22] nasal spray, [23] and sublingual tablets. [24] [25] Glover also conducted trials with bupropion (Zyban, a monocyclic antidepressant) [26] [27] [28] [29] [30] [31] [32] [33] and varenicline (Chantix, a nicotine receptor and partial agonist) which resulted in both being approved for use in the US. [34] [35] [36] [37] In addition, he studied the use of lobeline as a nicotine blocker, [38] [39] and various psychoactive substances including anti-depressants and anti-anxiety agents. [40] He also investigated rimonabant (a cannabinoid receptor inverse agonist), and 3′AmNic-rEPA (a nicotine conjugate vaccine) as smoking cessation aids. [1] [2]

He received research grants from the government U.S. Department of Education, Centers for Disease Control, National Cancer Institute, National Institute of Drug Abuse, and National Institutes of Health. Also, received grants from the manufacturers of smoking cessation aids and conducted various pharmaceutical testing for many companies. [1] [2] [12] [18] [20]

Professional accomplishments

Glover has authored or co-authored 146 peer-reviewed articles and an additional 63 professional publications from 1976 to 2021 and received approximately $33 million in grant funding. [1] He has delivered over 550 invited medical grand rounds/workshops on the subject to physicians and presented 335 national and international professional presentations to various medical and health professional organizations. [1] [2] [3] [4]

Glover was owner, publisher and editor of the American Journal of Health Behavior , Health Behavior and Policy Review and Tobacco Regulatory Science . [1] [2] [3] [4] In 2020, he sold his major portion of Health Behavior and Policy Review and in 2021 sold the American Journal of Health Behavior and Tobacco Regulatory Science. He was the founder (1997) and first president (1997–2001), of the American Academy of Health Behavior where he was named Fellow (1998), Research Laureate (2008) and awarded the Lifetime Achievement Award (2000) by the academy. [1] He was selected as fellow of the American School Health Association & the Royal Institute of Public Health. He was elected Fellow (1991) and received the Distinguished Scholar Award from the American Association of Health Education (2003). [41] Moreover, he received the AAHPERD Alliance Scholar Award being only the 4th health educator in its history to receive this award (2005). [42]

Public work

Glover's work appeared or featured on many television programs, including Dateline, 20/20, The Charlie Rose Show, Good Morning America , PM Magazine, Health Talk America, MD-TV, CBS Morning News, Peter Jennings News World Report, and NBC Evening News. His research has also been featured in numerous popular publications such as Ladies Home Journal, Newsweek, Reader's Digest, Seventeen, Time , and USA Today . [1] [2]

He served in various capacities primarily as reviewer and ad hoc reviewer for 20 key health academic journals and/or publications among these are the American Journal of Public Health, Addictive Behaviors, NCI Journal, Journal Clinical Advances in Smoking Cessation, Physician and Sports medicine, Medical Self-Care, Public Health Reports, American Journal of Health Education, Journal of School Health, Journal of Family Practice, Journal of Alcohol and Drug Education, Advances in Dental Research, Mayo Clinic Proceedings, Southern Medical Journal, Nicotine & Tobacco Research, Drug Discovery Today, and the Journal of the American Medical Association . [1] [2]

Criticism and controversy

The May–June 2021 edition of the American Journal of Health Behavior , "Special Issue on JUUL" generated controversy and negative feedback from some in the research and health communities when it was revealed that the entire issue and related research were funded by JUUL. The funding included additional fees stipulated to make the issue freely available to the public referred to as open access. [43] AJHB typically charges up to $180 yearly for access to their content by individuals and $375 by institutions. [44]

To avoid bias reviews, Glover solicited peer reviews of the studies being considered for the issue without disclosing that the studies were funded by JUUL. JUUL employees have indicated that all of the content for the issue was overseen by Glover. [45] As journal policy dictated, articles submitted to peers for review by Glover had the name of the sponsor redacted. When a tobacco regulatory scientist that reviewed and critiqued two studies for the journal questioned Glover about what she described as "fishy" aspects of the studies, Glover responded to the peer review group "It has been brought to my attention that some reviewers were unaware that the special issue on e-cigarettes is being funded by JUUL. My apologies for not alerting everyone. ... I honestly did not believe it to be a concern as the comprehensive reviews always purge weak or biased manuscripts. Funders are never revealed till after the review process and publication has been completed." This obfuscation was called "a horrible ethical breach" by Brian Jenssen, a pediatrician who specializes in tobacco policy research at Children's Hospital of Philadelphia. Glover's solicitation e-mail seeking reviews was also described as "unusual" in that it offered reviewers a cash payment if reviews were submitted within one week. Despite being listed online, a reviewer also noted that AJHB's practice of charging article authors "hefty fees" for their publication, which is atypical for academic journals, was not made clear. [46] Dr. Robert Taylor, an ethical investigator noted the fees with the number of articles published would easily fall well in the bottom of the fees charged for a special issue with open access.

After publication of the issue, three members of AJHB's editorial board resigned in protest. Glover stated that the journal followed its standard protocol for vetting before publication. Due to a cancer diagnosis, he retired soon after the issue was released. [43]

Related Research Articles

<span class="mw-page-title-main">Nicotine</span> Chemical stimulant produced by some plants

Nicotine is a naturally produced alkaloid in the nightshade family of plants and is widely used recreationally as a stimulant and anxiolytic. As a pharmaceutical drug, it is used for smoking cessation to relieve withdrawal symptoms. Nicotine acts as a receptor agonist at most nicotinic acetylcholine receptors (nAChRs), except at two nicotinic receptor subunits where it acts as a receptor antagonist.

<span class="mw-page-title-main">Smoking cessation</span> Process of discontinuing tobacco smoking

Smoking cessation, usually called quitting smoking or stopping smoking, is the process of discontinuing tobacco smoking. Tobacco smoke contains nicotine, which is addictive and can cause dependence. As a result, nicotine withdrawal often makes the process of quitting difficult.

<span class="mw-page-title-main">Bupropion</span> Substituted cathinone medication mainly used for depression and smoking cessation

Bupropion, sold under the brand name Wellbutrin among others, is an atypical antidepressant primarily used to treat major depressive disorder and to support smoking cessation. It is also popular as an add-on medication in the cases of "incomplete response" to the first-line selective serotonin reuptake inhibitor (SSRI) antidepressant. Bupropion has several features that distinguish it from other antidepressants: it does not usually cause sexual dysfunction, it is not associated with weight gain and sleepiness, and it is more effective than SSRIs at improving symptoms of hypersomnia and fatigue. Bupropion, particularly the immediate release formulation, carries a higher risk of seizure than many other antidepressants, hence caution is recommended in patients with a history of seizure disorder.

<span class="mw-page-title-main">Vaporizer (inhalation device)</span> Device to vaporize substances for inhalation

A vaporizer or vaporiser, colloquially known as a vape, is a device used to vaporize substances for inhalation. Plant substances can be used, commonly cannabis, tobacco, or other herbs or blends of essential oil. However, they are most commonly filled with a combination propylene glycol, glycerin, and drugs such as nicotine or tetrahydrocannabinol as a liquid solution.

<span class="mw-page-title-main">Nicotine replacement therapy</span> Treatment for tobacco use disorder

Nicotine replacement therapy (NRT) is a medically approved way to treat people with tobacco use disorder by taking nicotine through means other than tobacco. It is used to help with quitting smoking or stopping chewing tobacco. It increases the chance of quitting tobacco smoking by about 55%. Often it is used along with other behavioral techniques. NRT has also been used to treat ulcerative colitis. Types of NRT include the adhesive patch, chewing gum, lozenges, nose spray, and inhaler. The use of multiple types of NRT at a time may increase effectiveness.

Nicotine gum is a chewing gum containing the active ingredient nicotine polacrilex. It is a type of nicotine replacement therapy (NRT) used alone or in combination with other pharmacotherapy for smoking cessation and for quitting smokeless tobacco.

<span class="mw-page-title-main">Smokeless tobacco</span> Tobacco product used by means other than smoking.

Smokeless tobacco is a tobacco product that is used by means other than smoking. Their use involves chewing, sniffing, or placing the product between gum and the cheek or lip. Smokeless tobacco products are produced in various forms, such as chewing tobacco, snuff, snus, and dissolvable tobacco products. Smokeless tobacco products typically contain over 3000 constituents. All smokeless tobacco products contain nicotine and are therefore highly addictive. Quitting smokeless tobacco use is as challenging as smoking cessation.

<span class="mw-page-title-main">Cytisine</span> Chemical compound

Cytisine, also known as baptitoxine, cytisinicline, or sophorine, is an alkaloid that occurs naturally in several plant genera, such as Laburnum and Cytisus of the family Fabaceae. It has been used medically to help with smoking cessation. Although widely used for smoking cessation in Eastern Europe, cytisine remains relatively unknown beyond it. However, it has been found effective in several randomized clinical trials, including some in the United States and a large one in New Zealand, and is being investigated in additional trials in the United States and a non-inferiority trial in Australia in which it is being compared head-to-head with the smoking cessation aid varenicline. It has also been used entheogenically via mescalbeans by some Native American groups, historically in the Rio Grande Valley predating even peyote.

<span class="mw-page-title-main">Varenicline</span> Nicotinic receptor agonist

Varenicline, sold under the brand names Chantix and Champix among others, is a medication used for smoking cessation and for the treatment of dry eye disease. It is a nicotinic receptor partial agonist and a cholinergic agonist. When activated, this receptor releases dopamine in the nucleus accumbens, the brain's reward center, thereby reducing cravings and withdrawal symptoms associated with smoking cessation.

<span class="mw-page-title-main">Nicotine withdrawal</span> Process of withdrawing from nicotine addiction

Nicotine withdrawal is a group of symptoms that occur in the first few weeks after stopping or decreasing use of nicotine. Symptoms include intense cravings for nicotine, anger or irritability, anxiety, depression, impatience, trouble sleeping, restlessness, hunger or weight gain, and difficulty concentrating. Withdrawal symptoms make it harder to quit nicotine products, and most methods for quitting smoking involve reducing nicotine withdrawal. Quit smoking programs can make it easier to quit. Nicotine withdrawal is recognized in both the American Psychiatric Association Diagnostic and Statistical Manual and the WHO International Classification of Diseases.


Tobacco harm reduction (THR) is a public health strategy to lower the health risks to individuals and wider society associated with using tobacco products. It is an example of the concept of harm reduction, a strategy for dealing with the use of drugs. Tobacco smoking is widely acknowledged as a leading cause of illness and death, and reducing smoking is vital to public health.

<span class="mw-page-title-main">Electronic cigarette</span> Device that vaporizes a liquid nicotine solution for inhalation

An electronic cigarette (e-cigarette) or vape is a device that simulates tobacco smoking. It consists of an atomizer, a power source such as a battery, and a container such as a cartridge or tank filled with liquid. Instead of smoke, the user inhales vapor. As such, using an e-cigarette is often called "vaping". The atomizer is a heating element that vaporizes a liquid solution called e-liquid, which quickly cools into an aerosol of tiny droplets, vapor and air. E-cigarettes are activated by taking a puff or pressing a button. Some look like traditional cigarettes, and most kinds are reusable. The vapor mainly comprises propylene glycol and/or glycerin, usually with nicotine and flavoring. Its exact composition varies, and depends on several things including user behavior.

<span class="mw-page-title-main">Nicotine dependence</span> Chronic disease

Nicotine dependence is a state of dependence upon nicotine. Nicotine dependence is a chronic, relapsing disease defined as a compulsive craving to use the drug, despite social consequences, loss of control over drug intake, and emergence of withdrawal symptoms. Tolerance is another component of drug dependence. Nicotine dependence develops over time as a person continues to use nicotine. The most commonly used tobacco product is cigarettes, but all forms of tobacco use and e-cigarette use can cause dependence. Nicotine dependence is a serious public health problem because it leads to continued tobacco use, which is one of the leading preventable causes of death worldwide, causing more than 8 million deaths per year.

Nicotine Anonymous (NicA) is a twelve-step program founded in 1982 for people desiring to quit smoking and live free of nicotine. As of July 2017, there are over 700 face-to-face meetings in 32 countries worldwide with the majority of these meetings occurring in the United States, Iran, India, Canada, Brazil, the United Kingdom, Australia, Russia and in various online community and social media platforms.. NicA maintains that total abstinence from nicotine is necessary for recovery. NicA defines abstinence as “a state that begins when all use of nicotine ceases.

Schizophrenia and tobacco smoking have been historically associated. Smoking is known to harm the health of people with schizophrenia, and to negatively affect their cognition.

<span class="mw-page-title-main">Ovide F. Pomerleau</span> American psychologist (born 1940)

Ovide F. Pomerleau is an American psychologist who pioneered the development of behavioral medicine. He is best known for his work on self-management problems and addiction, focusing on the behavioral, biological, and genetic bases of tobacco smoking and nicotine dependence.

The scientific community in the United States and Europe are primarily concerned with the possible effect of electronic cigarette use on public health. There is concern among public health experts that e-cigarettes could renormalize smoking, weaken measures to control tobacco, and serve as a gateway for smoking among youth. The public health community is divided over whether to support e-cigarettes, because their safety and efficacy for quitting smoking is unclear. Many in the public health community acknowledge the potential for their quitting smoking and decreasing harm benefits, but there remains a concern over their long-term safety and potential for a new era of users to get addicted to nicotine and then tobacco. There is concern among tobacco control academics and advocates that prevalent universal vaping "will bring its own distinct but as yet unknown health risks in the same way tobacco smoking did, as a result of chronic exposure", among other things.

Jed Eugene Rose is an American academic professor, inventor and researcher in the field of nicotine and smoking cessation. Rose is presently the President and CEO of the Rose Research Center, LLC in Raleigh, North Carolina. Additionally, he is the Director of the Duke Center for Smoking Cessation at Duke University Medical Center.

Electronic cigarettes are marketed to smoking and non-smoking men, women, and children as being safer than cigarettes. In the 2010s, large tobacco businesses accelerated their marketing spending on vape products, similar to the strategies traditional cigarette companies used in the 1950s and 1960s.

Nicotine vaccine is a novel immunological strategy for treating nicotine addiction. Nicotine vaccine uses active immunization as the methodology to create polyclonal antibodies to the antigens, which is then used to treat drug abuse. The immune system is then able to identify nicotine as a foreign substance and initiate an immune reaction targeting the drug. As a result, the quantity of nicotine that enters the brain would decrease after receiving the vaccine. In preclinical studies, nicotine vaccines have demonstrated the ability to combat the negative effects of nicotine abuse, but none of the developed vaccines has been authorized for use in clinical trials as a smoking cessation strategy. Theoretically, the decrease of nicotine's rewarding effects should result in smoking cessation. Some companies have tested candidate vaccines in clinical trials, but evidence failed to show the adequate antibody responses or exhibit superior efficacy to factors concerning placebo.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 "Elbert D. Glover". University of Maryland | School of Public Health. Retrieved May 26, 2022.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Rowe, Steven. "Philosophy, Objectives and Scope of the Journal". Health Behavior and Policy Review. Retrieved May 26, 2022.
  3. 1 2 3 4 "Philosophy of the Journal". American Journal of Health Behavior. Retrieved May 26, 2022.
  4. 1 2 3 "Tobacco Regulatory Science (TRS)". Tobacco Regulatory Science. Retrieved May 26, 2022.
  5. 1 2 "AAHB Founders". American Academy of Health Behavior. Retrieved May 26, 2022.
  6. ↑ "Past Presidents". American Academy of Health Behavior. Retrieved May 26, 2022.
  7. 1 2 3 4 "Elbert D. Glover". University of Maryland | School of Public Health. Retrieved May 27, 2022.
  8. ↑ Brown V. (December 4, 1985). "Lawsuit Says Snuff Killed Teen-Ager". The Washington Post. ISSN 0190-8286. Retrieved August 1, 2017.
  9. ↑ Blumenfeld L. (April 2, 1992). "Focus". The Washington Post. ISSN 0190-8286. Retrieved August 1, 2017.
  10. ↑ Boul D. (August 23, 1987). "What's New in Tobacco; His and Hers Chewing and Dipping". The New York Times . ISSN 0362-4331. Retrieved August 1, 2017.
  11. ↑ Christen AG, Glover ED. "Smokeless tobacco: Seduction of youth". World Smoking & Health, 1981; 6 (2):20-24.
  12. 1 2 Schaefer SD, Henderson AH, Glover ED, Christen AG. "Patterns of use & incidence of smokeless tobacco consumption in school-age children". Archives of Otolaryngology, 1985;111(10):639–642.
  13. ↑ Edmundson EW, Glover ED, Alston PP, Holbert D. "Personality traits of smokeless tobacco users &nonusers: A comparison". The International Journal of the Addictions, 1987;22(7):671–683.
  14. ↑ Glover ED, Edmundson EW, Holbert D, Alston PP, Schroeder KL. "Prevalence & patterns of smokeless tobacco use in a Southeastern University". Journal of Drug Education, 1987;7(3):201 211. (PMID: 3681594)
  15. ↑ Glover ED, Schroeder KL, Henningfield JE, Severson HH, Christen AG. "An interpretative review of smokeless tobacco research in the United States: Part I". Journal of Drug Education, 1988;18(4):305–330.
  16. ↑ Glover ED, Schroeder KL, Henningfield JE, Severson HH, Christen AG. "An interpretative review of smokeless tobacco research in the United States: Part II". Journal of Drug Education, 1989;19(1):1–19.
  17. ↑ Glover ED, Laflin M, Edwards SW. "Age of initiation & switching patterns between smokeless tobacco & cigarettes among college students in the US". American Journal of Public Health, 1989;79(2):207–208.
  18. 1 2 Glover ED, Sachs DPL, Stitzer ML, Rennard SI, Wadland WC, Pomerleau OF, Nowak RT, Daughton DM, Glover PN, Hughes JR, Gross J. "Smoking cessation in highly dependent smokers with 4mg nicotine polacrilex". American Journal of Health Behavior, 1996;20(5):319-332.
  19. ↑ Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, Shadel W, Koslo R, Robbins B, Sorrentino J. "Comparative efficacy of rapid-release nicotine gum vs nicotine polacrilex gum in relieving smoking cue-provoked craving". Addiction, 2005;100(11):1720–1730.
  20. 1 2 Glover ED. "Transdermal nicotine patch for smoking cessation". New England Journal of Medicine, 1992;January 30, 326(5):344. PMID 1728741
  21. ↑ Daughton D, Fortmann S, Glover ED, Hatsukami D, Heatley S, Lichtenstein E, Repsher L, MillatmalT, Killen J, Nowak R, Ullrich F, Rennard S. "The smoking cessation efficacy of varying doses of nicotine patch delivery systems four years to five years post quit day". Preventive Medicine, 1999; 28:113–119.
  22. ↑ Rennard SI, Glover ED, Leischow S, Daughton D, Glover PN, Muramoto M, Franzon F, Danielsson T, Landfeldt B, Westin A. "Efficacy of nicotine inhaler in smoking reduction: a double-blind, randomized trial". Nicotine & Tobacco Research, 2006;8(4):555-564.
  23. ↑ Glover ED, Glover PN, Abrons HL, Franzon M. "An exploratory study in smoking cessation among COPD patients using nicotine nasal spray". American Journal of Health Behavior, 997;21(4):310-317.
  24. ↑ Glover ED, PN Glover, Franzon M, Sullivan CR, Howell GM, Keyes G. "A Nicotine Sublingual Tablet for Smoking Cessation: 6-Month Data". 10th World Conference on Tobacco or Health, Abstract Book, 1997;Aug 24-27, Beijing, China, 138.
  25. ↑ Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CL, Howell RM, Keyes GG, Nilsson F, Hobbs GR. "A comparison of a nicotine sublingual tablet & placebo for smoking cessation". Nicotine & Tobacco Research, 20024:441-450.
  26. ↑ Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. "A comparison of sustained-release bupropion & placebo for smoking cessation". New England Journal of Medicine, 1997;337:1195–1202.
  27. ↑ Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, Glover ED, Sachs DPL, Hurt RD. "Effectiveness of bupropion for smoking cessation in subjects with a history of major depression or alcoholism". British Journal of Psychiatry, 1999;174:173-178.
  28. ↑ Glover ED, Tucker VL, Winter PDOB. "Efficacy and tolerability of bupropion sustained-release for smoking cessation: a review of pivotal studies". The International Journal of Neuropsychopharmacology, 2000;3:Supplement 1;S326.
  29. ↑ Dale LC, Glover ED, Sachs DPL, Schroeder DR, Offord KP, Croghan IT, Hurt RD. "Bupropion for smoking cessation—predictors of successful outcome". Chest, 2001;119:1357–1364.
  30. ↑ Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DPL, Grasela T, DeVeaugh-Geiss J. "Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation". Nicotine & Tobacco Research, 2001;3(2):131-140.
  31. ↑ Glover ED, Tucker VL, Winter PD. "Efficacy and tolerability of bupropion SR for smoking cessation". World Journal of Biological Psychiatry, 2001;2(1)270S.
  32. ↑ Glover ED, Glover PN, Sullivan CR, Cerullo C, Hobbs GR. "A comparison of sustained-release bupropion & placebo for smokeless tobacco cessation". American Journal of Health Behavior, 2002;26;(5):386–393.
  33. ↑ Dale LC, Ebbert JO, Glover ED, Croghan IT, Schroeder DR, Severson HH, Hurt RD. "Bupropion SR for the treatment of smokeless tobacco use". Drug and Alcohol Dependence, 2007;90(1):56–63.
  34. ↑ Glover ED, Rath JM. "Varenicline: progress in the treatment of smoking cessation treatment". Expert Opinion Pharmacotherapy, 2007;8(11):1757-1767.
  35. ↑ Nides M, Glover ED, Reus V, Christen AG, Make BJ. "Varenicline versus bupropion or placebo for smoking cessation". American Journal of Health Behavior, 2008;32(6):664-675.
  36. ↑ Cooke CE, Glover ED, Xing S, Lee HY. "Failure to obtain Varenicline in members with pharmacy benefits". The American Journal of Pharmacy Benefits, 2011;May/June 3(3):e36–e40
  37. ↑ Glover ED, Rath JM. "Varenicline: progress in smoking cessation treatment". Expert Opinion on Pharmacotherapy, 2007;8(11):1757–1767. doi:10.1517/14656566.8.11.1757. ISSN 1465-6566. PMID 17685891.
  38. ↑ Glover ED, Leischow SJ, Rennard SI, Glover PN, Daughton D, Quiring JN, Schneider FH, Mione PJ. "Lobeline sulfate for smoking cessation: a pilot study". American Journal of Health Behavior, 1998;22(1):62–74.
  39. ↑ Glover ED, Rath J, Sharma E, Glover PN, Laflin MT, Tønnesen P, Repsher L, Quiring J. "A multi-center, phase-3 trial of lobeline sulfate for smoking cessation". American Journal of Health Behavior, 2010;34(1):101–109. doi:10.5993/AJHB.34.1.12
  40. ↑ Glover ED, Laflin MT, Schuh KJ, Schuh L, Nides M, Christen AG, Glover PN, Strnad JV. "A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers". Addiction, 2007;102:795–802.
  41. ↑ Glover ED.  "A new health education paradigm: uncommon thoughts about common matters".  AAHE scholar address. American Journal of Health Education, 2004;35(5):260–271.
  42. ↑ Glover ED. "Successfully treating nicotine dependence": AAHPERD scholar address. American Journal of Health Education, 2006;37(1):6–14.
  43. 1 2 Kaplan, Sheila (July 5, 2021). "Juul Is Fighting to Keep Its E-Cigarettes on the U.S. Market". The New York Times. ISSN   0362-4331 . Retrieved July 10, 2021.
  44. ↑ "Individual Subscription & Renewal". American Journal of Health Behavior. Retrieved July 10, 2021.
  45. ↑ Dayen, David (July 7, 2021). "Juul: Taking Academic Corruption to a New Level". The American Prospect . Retrieved August 2, 2021.
  46. ↑ McCullough, Marie (July 10, 2021). "In a fight for survival, Juul funds pro-vaping studies, then pays a scholarly journal to showcase them". The Philadelphia Inquirer . Retrieved July 10, 2021.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.